Rex Bionics (RXB) Share Price, News & Analysis

Company Overview

Rex Bionics Plc is engaged in the research and development, manufacture and commercialization of robotic devices designed to provide physiotherapy to and improve the physical and psychological well-being of people with mobility impairment as a result of spinal cord injury or other neurological trauma, such as stroke or traumatic brain injury, or neurodegenerative disease. The Company develops and commercializes ReX, the hands-free, self-supporting, independently controlled robotic walking device for use in the rehabilitation of people with major mobility impairment. The Company offers two principal products: ReX and ReX P (Personal), which are targeted respectively at the professional neuro-rehabilitation clinic and personal homecare markets. The Company utilizes RAPPER II, which is an open label, single arm, non-randomized, non-comparative registry study of Robot-Assisted Physiotherapy Exercises with the REX Robot powered exercise system preventing unsupported patient ambulation.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 314,960 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RXB Stock Analysis - Frequently Asked Questions

How do I buy shares of Rex Bionics?

Shares of RXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Manufacturing
• Industry: Electronic Computer Manufacturing
• Sub-Industry: Trading
• Current Symbol: LON:RXB
• CIK: N/A
• Web: www.rexbionicsuk.com
• Phone: 14089961010
• Fax: N/A
• Employees: 82,400
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A